There Has Never Been A Better Time To Buy AstraZeneca plc, Volkswagen AG And Carillion plc

So it's the new financial year. You can invest up to £15,240 in a stocks & shares ISA. After a rocky few months, global stock markets look cheap as chips. I firmly believe that this is a great time to go shopping for shares. But what will you buy?

///>

Here are three shares that you should buy right now.

AstraZeneca

Five years ago, most investors wouldn't touch pharmaceutical firm AstraZeneca(LSE: AZN) with a bargepole. With several key drugs tumbling down the patent cliff, and a disappointing drugs pipeline, this company's share price was plumbing the depths. The heyday of Big Pharma looked to be past.

But chief executive Pascal Soriot has turned round the fortunes of this drugs giant. A focus on world-class research, cutting edge biotechnology, and the development of money-spinning anti-cancer treatments have sparked a revival in profits, and the share price. It's no surprise that Pfizer recently tried to buy AZ. This is one of the pharmaceutical industry's most prized assets.

Yet the share price is off its highs, and I think there's more to come from this dividend dynamo. A 2016 P/E ratio of 14.54 and an income of 4.82% look good value.

Volkswagen

The emissions scandal that has hit Volkswagen (XETRA: VOW) over the past year has sent the share price tumbling. Yet my view is this 'crisis' is no worse that what carmaking rival Toyota went through just a few years ago and today Toyota is the most successful car firm in the world, its recall scandal already forgotten.

Anyone who has seen the new Audi A4 and the Volkswagen Passat will know that Volkswagen makes some of the best cars in the world. It doesn't look like a business that's going down the tubes.

That's why I think Volkswagen is currently oversold, and is a strong contrarian buy. A P/E of 9.56, with a dividend yield of 3.99%, means this is a bargain that shouldn't be missed.

Carillion

Carillion(LSE: CLLN) is one of Britain's leading building and support service firms, and is highly profitable. It's set to gain as a resurgent Britain invests more in its infrastructure over the coming years.

It made a net profit of £139m in 2015, and earnings are set to advance further. Yet this is a business going dirt cheap. The 2016 P/E ratio is 8.37, with a dividend yield of 6.79%.

By any measure, these are enticing numbers, and you should buy Carillion both for growth, and for the dividend.

If you're interested in dividend share opportunities, then our experts at the Fool have unearthed a little-known firm that's worth a much closer look. It's cheap, high-yielding, and a growing business.

Want to learn more? Well, just click on this linkto read A Top Income Share From The Motley Fool and it will be dispatched instantly to your inbox, completely free and without obligation.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.